XML 66 R52.htm IDEA: XBRL DOCUMENT v3.6.0.2
DEBT - Non-Recourse Notes (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 25 Months Ended 33 Months Ended
Feb. 28, 2017
Dec. 31, 2016
Apr. 17, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Apr. 17, 2016
Dec. 31, 2016
Apr. 30, 2014
Debt                  
Interest added to the principal balance of the non-recourse term notes due 2029       $ 855 $ 22,635 $ 20,527      
Long-term debt   $ 728,173   728,173 748,271     $ 728,173  
GSK | Long-acting beta agonist (LABA) collaboration                  
Debt                  
Royalty Revenue   46,800   146,507 66,887 $ 18,417      
Non-Recourse Notes Payable due 2029                  
Debt                  
Interest added to the principal balance of the non-recourse term notes due 2029       900 22,700     44,000  
Debt prepayment premium (as a percent)             5.00%    
Long-term debt   $ 487,189   487,189 $ 493,162     $ 487,189  
Non-Recourse Notes Payable due 2029 | Future                  
Debt                  
Debt prepayment premium (as a percent)     2.50%            
Non-Recourse Notes Payable due 2029 | GSK                  
Debt                  
Payment of principal       $ 6,800          
Non-Recourse Notes Payable due 2029 | GSK | Future                  
Debt                  
Payment of principal $ 7,800                
Non-Recourse Notes Payable due 2029 | GSK | Long-acting beta agonist (LABA) collaboration                  
Debt                  
Percentage of royalties from global net sales to secure debt                 40.00%
Non-Recourse Notes Payable due 2029 | Private Placement                  
Debt                  
Non-Recourse Debt                 $ 450,000
Interest rate (as a percent)   9.00%   9.00%       9.00% 9.00%
Debt issuance costs                 $ 15,300